Health care professionals who were trained to treat infections with Botox were forced to do so as a result of the federal healthcare overhaul, according to a new study.
The study by researchers at Georgetown University found that those who received Botox to treat skin cancer in the past two decades had a higher likelihood of being diagnosed with other types of cancer in future.
A new study found that more than 40 percent of health care workers who were certified in the field of skin cancer prevention received Botax before they received an internship at a health care facility, according the study by the Georgetown University Center for Nursing Research.
The researchers, led by Dr. Paul D. Smith, an assistant professor in Georgetown’s School of Nursing, looked at data from a National Cancer Institute-sponsored survey of more than 8,000 nursing practitioners.
The survey included questions about how they used Botox in the clinic and how they experienced complications from the procedure.
Dressings were not included in the analysis.
Some of the questions were included because they are included in current health care standards, the study said.
The results, published Monday in the journal JAMA Internal Medicine, showed that health care professionals with more than a two-year history of Botox use were 20 percent more likely to develop cancer than health care providers who received a non-botox training.
More than 1 in 10 health care practitioners who received botox for a skin cancer diagnosis also reported that they were diagnosed with another type of cancer, compared to 3 in 10 healthcare providers who did not receive Botox training, according, the researchers wrote.
“We found that patients who have received Botoxin are three times more likely than the general population to develop other types [of cancer],” Smith said.
Smith noted that the research is not conclusive about Botox’s effectiveness in treating other types, and that it is not known how long Botox can be effective in preventing other types.
He said the findings also did not prove that Botox was safer than conventional surgeries or surgeries without Botox, but they did suggest that Botoxin could be effective at reducing complications from skin cancer.
Other studies have found that BotOX has reduced skin cancers and improved overall outcomes, Smith said, and there is evidence that it can also be used to treat other skin cancers.
There are currently more than 1.5 million people with skin cancers, according an estimate by the National Cancer Prevention Council.
At least some of the benefits of Botoxin-based surgery, Smith and his colleagues found, could be attributed to the ability to cut into tumors, the Journal of the American Medical Association wrote in a commentary accompanying the study.
While Botox does not have an FDA approval, Smith noted that it has been widely used for years in the United States for cancer patients.
In recent years, there has been a push to expand the use of BotX as a treatment for a range of skin cancers including melanoma, squamous cell carcinoma and melanoma of the pancreas.
Smith and his co-authors wrote that BotX has not been tested for its effectiveness in other cancers, but that they did find that it reduced the risk of developing other types skin cancers compared to those who did receive Botoxin training.
They also said that some health care facilities were reluctant to treat patients with Botoxin who were not qualified.
For example, there are currently no approved trials for skin cancer, Smith wrote.
“We have not identified the mechanism of action for Botox or any other agent to determine if it is safe or effective in treating skin cancer.”
Follow @ABCNewsHealth on Twitter.